Literature DB >> 3491853

Anti-idiotypic mechanisms involved in suppression of a mouse B cell lymphoma, BCL1.

A J George, A L Tutt, F K Stevenson.   

Abstract

Immunization of BALB/c mice with idiotypic IgM rescued by hybridization from the syngeneic BCL1 lymphoma protects specifically against challenge with tumor cells, with 83% surviving greater than 100 days compared with controls (38 +/- 10 days). Spleens from long-term survivors (greater than 6 mo) with no macroscopically visible tumor, when examined with anti-idiotypic antibody, showed a range of apparently dormant tumor with BCL1 cells present at 2 to 50% of total. A spectrum of protection against tumor resulted from immunization, and tumor emerging in the period 53 to 173 days postpassage was investigated for expression of idiotype. It was found that cells from individual mice expressed variable amounts of idiotypic IgM at the cell surface, although it was always detectable in the intracellular compartment. Unlike typical BCL1 cells, tumor cells developing in immune spleens often secreted little idiotypic IgM either in vitro or in vivo. This modulation of expression and secretion of idiotype was detected even in the apparent absence of serum anti-idiotypic antibody. On passage of spleen cells from the long-term survivors into naive animals, BCL1 tumor developed and killed the recipients in a way indistinguishable from routine tumor passage. These tumor cells, however, both expressed and secreted IgM of the same idiotype as the original tumor. It appears therefore that tumor development in immunized mice is suppressed by a process that includes modulation but not selection of the tumor cell idiotypic determinants. Analysis of possible mechanisms of suppression revealed the presence of cytotoxic anti-idiotypic antibody at variable levels in sera of immunized mice, and splenic T cells that proliferated specifically in response to idiotypic IgM. Only low levels of cytotoxic T cells were found. Passive transfer studies demonstrated a major role for antibody in protection against tumor, with no significant enhancement by immune lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3491853

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

Review 1.  Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures.

Authors:  Maurizio Bendandi
Journal:  Nat Rev Cancer       Date:  2009-09       Impact factor: 60.716

2.  A vaccine directed to B cells and produced by cell-free protein synthesis generates potent antilymphoma immunity.

Authors:  Patrick P Ng; Ming Jia; Kedar G Patel; Joshua D Brody; James R Swartz; Shoshana Levy; Ronald Levy
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-08       Impact factor: 11.205

3.  Humanized mouse G6 anti-idiotypic monoclonal antibody has therapeutic potential against IGHV1-69 germline gene-based B-CLL.

Authors:  De-Kuan Chang; Vinodh B Kurella; Subhabrata Biswas; Yuval Avnir; Jianhua Sui; Xueqian Wang; Jiusong Sun; Yanyan Wang; Madhura Panditrao; Eric Peterson; Aimee Tallarico; Stacey Fernandes; Margaret Goodall; Quan Zhu; Jennifer R Brown; Roy Jefferis; Wayne A Marasco
Journal:  MAbs       Date:  2016-03-10       Impact factor: 5.857

4.  Cytotoxic T cells generated against heteroclitic peptides kill primary tumor cells independent of the binding affinity of the native tumor antigen peptide.

Authors:  Katja Mauerer Zirlik; David Zahrieh; Donna Neuberg; John G Gribben
Journal:  Blood       Date:  2006-08-10       Impact factor: 22.113

Review 5.  Immunotherapy for lymphomas.

Authors:  John M Timmerman
Journal:  Int J Hematol       Date:  2003-06       Impact factor: 2.490

6.  Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response.

Authors:  L W Kwak; H A Young; R W Pennington; S D Weeks
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

7.  Immunotherapy of B lymphoma by anti-idiotype antibodies: characterization of variant tumour cells appearing a long time after the initial tumour inoculation.

Authors:  M Taya; J Haimovich
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

8.  Cancer dormancy: isolation and characterization of dormant lymphoma cells.

Authors:  E Yefenof; L J Picker; R H Scheuermann; T F Tucker; E S Vitetta; J W Uhr
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

9.  Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma.

Authors:  John M Timmerman; Julie M Vose; Debra K Czerwinski; Wen-Kai Weng; Diane Ingolia; Martha Mayo; Dan W Denney; Ronald Levy
Journal:  Leuk Lymphoma       Date:  2009-01

10.  Lyn tyrosine kinase signals cell cycle arrest but not apoptosis in B-lineage lymphoma cells.

Authors:  R H Scheuermann; E Racila; T Tucker; E Yefenof; N E Street; E S Vitetta; L J Picker; J W Uhr
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.